Biohaven Ltd.BHVN
What Biohaven Ltd. does.
Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. We are advancing our innovative portfolio of therapeutics, leveraging our proven drug development experience and multiple proprietary drug development platforms.
On October 3, 2022, Biohaven Pharmaceutical Holding Company Ltd. (the “Former Parent”) completed the distribution to holders of its common shares of all of our outstanding common shares and the spin-off of Biohaven Ltd. from the Former Parent (the “Separation”). As a result of the Separation, Biohaven became an independent, publicly traded company as of October 3, 2022, and commenced regular way trading under the symbol “BHVN”’ on the New York Stock Exchange on October 4, 2022.
In the fourth quarter of 2025, we initiated strategic portfolio and cost-optimization measures to prioritize three key, late-stage, clinical programs that we believe have the greatest potential for value generation. Our key clinical programs include Kv7 ion channel modulation for epilepsy; Molecular Degrader of Extracellular Proteins (“MoDE”) and Targeted Removal of Aberrant Protein ("TRAP") extracellular protein degradation for immunological diseases; and myostatin-activin pathway targeting agent for neuromuscular and metabolic diseases, including obesity (collectively, the "key programs"). The product candidates chart below summarizes our most advanced programs, including those that are key clinical stage programs and some of our preclinical programs that are beginning to advance to the clinic.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$118.7M | -$213.8M | -$570.3M | -$408.2M | -$846.4M | -$738.8M |
| Free cash flow | -$77.1M | -$146.8M | -$303.8M | -$334.8M | -$586.5M | -$610.2M |
More on BHVN.
- Biohaven Ltd. summary
- Biohaven Ltd. financial statements
- Biohaven Ltd. key metrics
- Biohaven Ltd. health scores and style box
- Biohaven Ltd. earnings
- Biohaven Ltd. dividends
- Biohaven Ltd. valuation
- Biohaven Ltd. ownership and insiders
- Biohaven Ltd. peers
Figures from Biohaven Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.